Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BIOVIE INC.

Get SEC filing alerts via email and in your feed for BIOVIE INC.

BIVI

BIOVIE INC.

About BIOVIE INC.

BioVie Inc. is a clinical-stage biopharmaceutical company developing innovative drug therapies targeting neurological and neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases, long COVID, and advanced liver cirrhosis. Its key products include bezisterim, an oral anti-inflammatory agent addressing neuroinflammation and insulin resistance, and BIV201, a novel terlipressin formulation for liver disease complications. BioVie focuses on advancing clinical trials and leveraging proprietary formulations and intellectual property to address significant unmet medical needs.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from BIOVIE INC.

1
1
BIOVIE INC. BioVie Inc. Reports $5.3 Million Net Loss for Q1 2026, Driven by Increased R&D Expenses

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
BIOVIE INC. BioVie Inc. Reports $6.1 Million Net Loss in Q2 FY 2026, Advances Clinical Programs

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
BIOVIE INC. BioVie Inc. Reports $5.1 Million Net Loss and Increases R&D Spending in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BIOVIE INC. BioVie Inc. Reports $17.5 Million Net Loss for Fiscal Year Ending June 30, 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BIOVIE INC. BioVie Inc. Reports Improved Financial Results, Net Loss Decrease, and Ongoing Clinical Trials for Innovative Drug Therapies

Via official filing (AI summary) | over 1 year ago | 0 comments